Delgocitinib Cream Outperforms Alitretinoin in Trial
April 28, 2025
-
3 min
Results from the DELTA FORCE study, a phase III trial, demonstrated the superior efficacy and safety of delgocitinib cream over oral alitretinoin in adult patients with severe chronic hand eczema. Delgocitinib cream showed significantly greater reduction in Hand Eczema Severity Index scores, higher improvement in Investigator’s Global Assessment, relief from itch and pain, and better quality of life compared to alitretinoin. The study suggests delgocitinib cream as a potential nonsystemic treatment alternative for this condition.
1. Delgocitinib cream was more effective and safer than oral alitretinoin in treating severe chronic hand eczema. 2. Delgocitinib showed a significantly greater reduction in Hand Eczema Severity Index scores at week 12. 3. More patients in the delgocitinib group achieved at least a 90% improvement in HECSI scores. 4. Delgocitinib provided greater relief from itch and pain compared to alitretinoin. 5. Delgocitinib is a nonsteroidal topical pan–Janus kinase (JAK) inhibitor targeting multiple inflammatory pathways. 6. The study supports delgocitinib cream as a potential nonsystemic treatment alternative for severe chronic hand eczema.
Listen Tab content
